1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Summary
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  01:44 2022-08-11 am EDT
0.0260 AUD    0.00%
08/10Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody

06/14/2022 | 04:31am EDT


© MT Newswires 2022
All news about PATRYS LIMITED
08/10Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
07/04Patrys Produces Antibody Drug at Commercial Scale
MT
07/03Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run
CI
06/14Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody
MT
06/03Patrys Secures Grant Funding to Develop Brain Cancer Drug
MT
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
04/14PATRYS : Application for quotation of securities - PAB
PU
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
PU
More news
Financials
Sales 2021 1,34 M 0,95 M 0,95 M
Net income 2021 -4,06 M -2,88 M -2,88 M
Net cash 2021 10,9 M 7,74 M 7,74 M
P/E ratio 2021 -22,2x
Yield 2021 -
Capitalization 53,5 M 37,9 M 37,9 M
EV / Sales 2020 11,5x
EV / Sales 2021 67,8x
Nbr of Employees 10
Free-Float 70,9%
Chart PATRYS LIMITED
Duration : Period :
Patrys Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PATRYS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
James A. Campbell Chief Executive Officer, MD & Director
John Douglas Read Non-Executive Chairman
Valentina Dubljevic Vice President-Scientific & Clinical Development
Michael J. Stork Deputy Chairman & Non-Executive Director
Suzy Jones Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PATRYS LIMITED-29.73%38
MODERNA, INC.-31.38%68 174
LONZA GROUP AG-26.76%44 940
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396
ALNYLAM PHARMACEUTICALS, INC.36.81%27 846